Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yuyu Pharma Inc. (000227:KRX), powered by AI.
Yuyu Pharma Inc. is currently trading at ₩10,610. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yuyu Pharma Inc. on Alpha Lenz.
Yuyu Pharma Inc.'s P/E ratio is 0.4.
“Yuyu Pharma Inc. trades at a P/E of 0.4 (undervalued) with modest ROE of 6.4%.”
Ask for details →Yuyu Pharma Inc. is a prominent pharmaceutical company, primarily engaged in the development, manufacture, and distribution of medical products, specifically focusing on pharmaceuticals and health supplements. The company's core mission is to improve health outcomes by offering innovative and effective therapeutic solutions. Yuyu Pharma Inc. plays a significant role in the healthcare sector, particularly in the areas of cardiovascular, metabolic, and central nervous system disorders. Additionally, the company's product lineup includes both prescription and over-the-counter medications, catering to diverse medical needs. This diversification allows Yuyu Pharma to address various market demands and remain resilient amidst changing industry dynamics. Headquartered in South Korea, Yuyu Pharma Inc. has established a significant presence in both domestic and international markets, leveraging its research and development capabilities to stay competitive within the global pharmaceutical industry. Its consistent focus on quality and innovation underscores its strategic importance in the health and wellness domains, contributing actively to advancements in medical treatments and patient care across regions.
“Yuyu Pharma Inc. trades at a P/E of 0.4 (undervalued) with modest ROE of 6.4%.”
Ask for details →Yuyu Pharma Inc. (ticker: 000227) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 254 employees. Market cap is $3.5B.
The current price is ₩10,610 with a P/E ratio of 0.42x and P/B of 0.03x.
ROE is 6.40% and operating margin is 7.82%. Annual revenue is $140.9B.